0000950170-23-071115.txt : 20231218
0000950170-23-071115.hdr.sgml : 20231218
20231218163019
ACCESSION NUMBER: 0000950170-23-071115
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231214
FILED AS OF DATE: 20231218
DATE AS OF CHANGE: 20231218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cutler Adam D.
CENTRAL INDEX KEY: 0001722673
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41837
FILM NUMBER: 231494158
MAIL ADDRESS:
STREET 1: 9301 AMBERGLEN BOULEVARD, SUITE 100
STREET 2: C/O MOLECULAR TEMPLATES, INC.
CITY: AUSTIN
STATE: TX
ZIP: 78729
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mural Oncology plc
CENTRAL INDEX KEY: 0001971543
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 EARLSFORT TERRACE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 T380
BUSINESS PHONE: 353 1 905 8020
MAIL ADDRESS:
STREET 1: 10 EARLSFORT TERRACE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 T380
FORMER COMPANY:
FORMER CONFORMED NAME: Mural Oncology Ltd
DATE OF NAME CHANGE: 20230403
FORMER COMPANY:
FORMER CONFORMED NAME: Pistachiovale Ltd
DATE OF NAME CHANGE: 20230329
4
1
ownership.xml
4
X0508
4
2023-12-14
0001971543
Mural Oncology plc
MURA
0001722673
Cutler Adam D.
C/O MURAL ONCOLOGY PLC
10 EARLSFORT TERRACE
DUBLIN 2
L2
D02 T380
IRELAND
false
true
false
false
Chief Financial Officer
false
Ordinary Shares
2023-12-14
4
A
false
78859
0.00
A
78859
D
Stock Option (right to buy)
3.61
2023-12-14
4
A
false
146452
0.00
A
2033-12-13
Ordinary Shares
146452
146452
D
Consists of ordinary shares issuable under 78,859 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of October 30, 2023, subject to the reporting person's continued service with the Issuer.
This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on October 30, 2024 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer.
/s/ Maiken Keson-Brookes, attorney-in-fact for Adam D. Cutler
2023-12-18